Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsAlternative strategies for proof-of-principle studies of antibacterial agentsStructural Insights into the Anti-methicillin-resistant Staphylococcus aureus (MRSA) Activity of CeftobiproleCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaComparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole.In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumoniaCeftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes.Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.Fosfomycin: use beyond urinary tract and gastrointestinal infections.In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitalsCurrent and novel antibiotics against resistant Gram-positive bacteriaEmerging agents to combat complicated and resistant infections: focus on ceftobiproleSynergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in TaiwanPharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strainsAnti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.Antimicrobial therapy of Staphylococcus aureus bloodstream infection.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.Current challenges in treating MRSA: what are the options?Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update.Ceftobiprole: a new broad spectrum cephalosporin.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance.Selective in vivo and in vitro activities of 3,3'-4-nitrobenzylidene-bis-4-hydroxycoumarin against methicillin-resistant Staphylococcus aureus by inhibition of DNA polymerase III.A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates.Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.β-lactams against emerging 'superbugs': progress and pitfalls.In vitro antibacterial activity of NB-003 against Propionibacterium acnes.History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus.In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms
P2860
Q24646677-788C3C2D-A6C1-435F-9246-574E20347A74Q26850895-C3F42175-9E79-4ADA-9F2F-F5191366D87DQ27670836-2AD60DD1-E0C0-464C-B364-2515688A9281Q28085517-F8BC63F6-A9FD-4B9C-83E3-B3EB34DBD1F4Q30369604-61DA0E28-B93F-4455-AF7B-8473D335A207Q33559139-BACA45F8-E1A3-46BC-89D7-AE24FBA9C7CDQ34187667-B7430FDF-FBCA-498B-941E-C47BB5974BC1Q34414748-5F6D0E00-6E0B-42C0-B35F-4BE20CC1F573Q34433342-FEF43DEC-8134-48B0-BBE4-DD97024E0B07Q34564481-D7780791-63B4-432B-ADA4-40C701ECC708Q34624359-71F43924-AA6B-4267-8081-B0FED87B836EQ34774778-6D612180-2C08-4049-875B-AF793B63931EQ34973784-BE16F728-D69E-428F-A0E9-B728F876CC2BQ35026521-31BD34AB-628C-46AC-8289-80ACF58C24BCQ35026567-3C97847F-7F13-40EB-9927-F5544F4A75D6Q35806369-DF329DCC-3EC0-459E-A147-61EBB9200154Q35879080-9FE6B892-3D71-47F9-AE92-EBD4900D1A54Q36422630-9BFA8511-66E5-4ACD-9A98-E98A48F4A7C7Q36497876-8DB3A3C1-60EE-41A6-AC11-FC95D1117AB2Q36744877-EBA1AABC-692B-41F9-9AB4-CBEE24F09DE6Q36763997-B9A6C3F1-EAF8-423C-9BB1-DEF549E1E713Q36968150-0684757A-8C17-49E7-9E87-4A5D349ADC2AQ37071199-23983759-E8D1-452D-AC13-57B8F8E4D8A3Q37162872-1C25C3BE-99AE-48CE-9DA5-6FF1E8861383Q37291338-8BF293CC-7325-4010-99DB-CC962DF51FFFQ37392891-7E04D8BE-6292-4C47-BA35-7756EC47E308Q37461413-055BED6C-4E60-4B6C-B712-F5E14124818BQ37514259-01F3DFC8-041F-4AA7-8258-03173DBD7958Q37519733-7A5E7EB0-4BCD-4292-9697-55280B5A46B3Q37593094-FD5C6EE7-FBC0-42AF-A54B-DA74A5DAAB70Q37717901-510761EA-DBFF-4B13-8622-29AF797D9C43Q37736231-DF13FFF4-31BF-4F27-A79A-10463981DD45Q37899151-8EF292B0-190B-4718-8A0F-403427C19B52Q38099393-C684AC25-8F0D-46FC-9BDD-77227613B952Q38177344-8FB457C7-20EA-4950-93D7-A4171D2C6DE0Q38283280-75AA303C-21EE-4196-AA49-872DEF173E25Q38536137-D8C34AA9-7363-4A45-86AD-35C1FDD506B0Q38899451-CE5DE0E3-9094-4FF5-9C10-1FA1B6409937Q39077347-632A07D4-8BC2-45D4-8918-C077745051FCQ39077719-E1527A79-C146-43A1-A1B8-84E3DAD03769
P2860
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
@en
type
label
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
@en
prefLabel
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
@en
P2093
P2860
P1476
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
@en
P2093
Lois M Ednie
Peter C Appelbaum
Stuart Shapiro
Tatiana Bogdanovich
P2860
P304
P356
10.1128/AAC.49.10.4210-4219.2005
P407
P577
2005-10-01T00:00:00Z